Standard

Novel 1-amidino-4-phenylpiperazines as potent agonists at human taar1 receptor : Rational design, synthesis, biological evaluation and molecular docking studies. / Francesconi, Valeria; Cichero, Elena; Kanov, Evgeny V.; Laurini, Erik; Pricl, Sabrina; Gainetdinov, Raul R.; Tonelli, Michele.

In: Pharmaceuticals, Vol. 13, No. 11, 391, 11.2020, p. 1-26.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Francesconi, Valeria ; Cichero, Elena ; Kanov, Evgeny V. ; Laurini, Erik ; Pricl, Sabrina ; Gainetdinov, Raul R. ; Tonelli, Michele. / Novel 1-amidino-4-phenylpiperazines as potent agonists at human taar1 receptor : Rational design, synthesis, biological evaluation and molecular docking studies. In: Pharmaceuticals. 2020 ; Vol. 13, No. 11. pp. 1-26.

BibTeX

@article{fa2416c1df5f4f3ea1f80432c8fc8f3c,
title = "Novel 1-amidino-4-phenylpiperazines as potent agonists at human taar1 receptor: Rational design, synthesis, biological evaluation and molecular docking studies",
abstract = "Targeting trace amine-associated receptor 1 (TAAR1) receptor continues to offer an intriguing opportunity to develop innovative therapies in different pharmacological settings. Pursuing our endeavors in the search for effective and safe human TAAR1 (hTAAR1) ligands, we synthesized a new series of 1-amidino-4-phenylpiperazine derivatives (1–16) based on the application of a combined pharmacophore model/scaffold simplification strategy for an in-house series of biguanide-based TAAR1 agonists. Most of the novel compounds proved to be more effective than their prototypes, showing nanomolar EC50 values in functional activity at hTAAR1 and low general cytotoxicity (CC50 > 80 µM) when tested on the Vero-76 cell line. In this new series, the main determinant for TAAR1 agonism ability appears to result from the appropriate combination between the steric size and position of the substituents on the phenyl ring rather than from their different electronic nature, since both electron-withdrawing and electron donor groups are permitted. In particular, the ortho-substitution seems to impose a more appropriate spatial geometry to the molecule that entails an enhanced TAAR1 potency profile, as experienced, in the following order, by compounds 15 (2,3-diCl, EC50 = 20 nM), 2 (2-CH3, EC50 = 30 nM), 6 (2-OCH3, EC50 = 93 nM) and 3 (2-Cl, EC50 = 160 nM). Apart from the interest in them as valuable leads for the development of promising hTAAR1 agonists, these simple small molecules have further allowed us to identify the minimal structural requirements for producing an efficient hTAAR1 targeting ability.",
keywords = "1-amidino-4-phenylpiperazines, Docking studies, Human TAAR1 agonists, Pharmacophore model, Trace amine-associated receptor 1 (TAAR1)",
author = "Valeria Francesconi and Elena Cichero and Kanov, {Evgeny V.} and Erik Laurini and Sabrina Pricl and Gainetdinov, {Raul R.} and Michele Tonelli",
note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2020",
month = nov,
doi = "10.3390/ph13110391",
language = "English",
volume = "13",
pages = "1--26",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "MDPI AG",
number = "11",

}

RIS

TY - JOUR

T1 - Novel 1-amidino-4-phenylpiperazines as potent agonists at human taar1 receptor

T2 - Rational design, synthesis, biological evaluation and molecular docking studies

AU - Francesconi, Valeria

AU - Cichero, Elena

AU - Kanov, Evgeny V.

AU - Laurini, Erik

AU - Pricl, Sabrina

AU - Gainetdinov, Raul R.

AU - Tonelli, Michele

N1 - Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2020/11

Y1 - 2020/11

N2 - Targeting trace amine-associated receptor 1 (TAAR1) receptor continues to offer an intriguing opportunity to develop innovative therapies in different pharmacological settings. Pursuing our endeavors in the search for effective and safe human TAAR1 (hTAAR1) ligands, we synthesized a new series of 1-amidino-4-phenylpiperazine derivatives (1–16) based on the application of a combined pharmacophore model/scaffold simplification strategy for an in-house series of biguanide-based TAAR1 agonists. Most of the novel compounds proved to be more effective than their prototypes, showing nanomolar EC50 values in functional activity at hTAAR1 and low general cytotoxicity (CC50 > 80 µM) when tested on the Vero-76 cell line. In this new series, the main determinant for TAAR1 agonism ability appears to result from the appropriate combination between the steric size and position of the substituents on the phenyl ring rather than from their different electronic nature, since both electron-withdrawing and electron donor groups are permitted. In particular, the ortho-substitution seems to impose a more appropriate spatial geometry to the molecule that entails an enhanced TAAR1 potency profile, as experienced, in the following order, by compounds 15 (2,3-diCl, EC50 = 20 nM), 2 (2-CH3, EC50 = 30 nM), 6 (2-OCH3, EC50 = 93 nM) and 3 (2-Cl, EC50 = 160 nM). Apart from the interest in them as valuable leads for the development of promising hTAAR1 agonists, these simple small molecules have further allowed us to identify the minimal structural requirements for producing an efficient hTAAR1 targeting ability.

AB - Targeting trace amine-associated receptor 1 (TAAR1) receptor continues to offer an intriguing opportunity to develop innovative therapies in different pharmacological settings. Pursuing our endeavors in the search for effective and safe human TAAR1 (hTAAR1) ligands, we synthesized a new series of 1-amidino-4-phenylpiperazine derivatives (1–16) based on the application of a combined pharmacophore model/scaffold simplification strategy for an in-house series of biguanide-based TAAR1 agonists. Most of the novel compounds proved to be more effective than their prototypes, showing nanomolar EC50 values in functional activity at hTAAR1 and low general cytotoxicity (CC50 > 80 µM) when tested on the Vero-76 cell line. In this new series, the main determinant for TAAR1 agonism ability appears to result from the appropriate combination between the steric size and position of the substituents on the phenyl ring rather than from their different electronic nature, since both electron-withdrawing and electron donor groups are permitted. In particular, the ortho-substitution seems to impose a more appropriate spatial geometry to the molecule that entails an enhanced TAAR1 potency profile, as experienced, in the following order, by compounds 15 (2,3-diCl, EC50 = 20 nM), 2 (2-CH3, EC50 = 30 nM), 6 (2-OCH3, EC50 = 93 nM) and 3 (2-Cl, EC50 = 160 nM). Apart from the interest in them as valuable leads for the development of promising hTAAR1 agonists, these simple small molecules have further allowed us to identify the minimal structural requirements for producing an efficient hTAAR1 targeting ability.

KW - 1-amidino-4-phenylpiperazines

KW - Docking studies

KW - Human TAAR1 agonists

KW - Pharmacophore model

KW - Trace amine-associated receptor 1 (TAAR1)

UR - http://www.scopus.com/inward/record.url?scp=85096102119&partnerID=8YFLogxK

U2 - 10.3390/ph13110391

DO - 10.3390/ph13110391

M3 - Article

AN - SCOPUS:85096102119

VL - 13

SP - 1

EP - 26

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 11

M1 - 391

ER -

ID: 87888693